ArticleBirth defects research2026
The Effect of Maternal Pertussis Vaccination on Neonatal Health Outcomes in the Dutch Pregnancy Drug Register.
Article in Birth defects research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe currently high pertussis-related morbidity and mortality among infants has led to increased international attention for pertussis vaccination during pregnancy. We studied the safety of maternal pertussis vaccination in the Netherlands with respect to neonatal health.
methodsData from the cohort the Dutch Pregnancy Drug Register were used. Pregnant participants self-reported their pertussis vaccination and the health outcomes of their offspring. Participants with a singleton live birth ≥ 24 weeks gestation were included. Using log-binomial regression analysis and correction for confounders, we studied the risk of maternal pertussis vaccination on various neonatal health outcomes. Moreover, we compared differences in health outcomes between second and third trimester vaccinations.
resultsThe study population included 10,280 participants (74.8% vaccinated against pertussis during pregnancy and 25.3% not). The adjusted risk ratio (RR) was: 1.01 (95% confidence interval [CI]: 0.82-1.23) for small for gestational age; 0.90 (95% CI: 0.73-1.11) for large for gestational age; 0.86 (95% CI: 0.59-1.25) for low birth weight; 1.06 (95% CI: 0.90-1.25) for neonatal health problems, and 0.68 (95% CI: 0.47-0.99) for infant hospitalization due to (suspicion of) infection. Also for the secondary outcomes neonatal death, low Apgar score, and neonatal intensive care unit admission, no increased risk after maternal pertussis vaccination was observed. There was no difference in neonatal health outcomes between second and third trimester pertussis vaccinations.
conclusionsThe maternal pertussis vaccination did not increase the risk of several adverse neonatal health outcomes, confirming the safety of pertussis vaccination during pregnancy with respect to neonatal health outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.